(WTNH) — Moderna announced their authorized booster (50 µg of mRNA-1273) increases neutralizing antibody levels against the omicron variant on Monday.
“The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. However, these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring,” said Stéphane Bancel, Chief Executive Officer of Moderna. “To respond to this highly transmissible variant, Moderna will continue to rapidly advance an Omicron-specific booster candidate into clinical testing in case it becomes necessary in the future. We will also continue to generate and share data across our booster strategies with public health authorities to help them make evidence-based decisions on the best vaccination strategies against SARS-CoV-2.”
As of right now, Modern’a first line of defense against the omicron variant will be a booster dose of mRNA-1273 as Moderna will continue to develop an omicron-specific variant vaccine. Trails are expected to start in early 2022.
For more information, head to investors.modernatx.com.